Compare Stocks: AKBA, AVTX, SANA, and JANX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.87 -2.6%	$1.16	$0.82 ▼ $3.34	$247.51M	0.26	4.05 million shs	4.09 million shs
AVTX Avalo Therapeutics	$19.45 -0.5%	$17.69	$8.41 ▼ $24.27	$1.05B	0.8	837,998 shs	391,152 shs
JANX Janux Therapeutics	$16.00 -4.0%	$15.24	$12.12 ▼ $35.34	$1.02B	2.5	707,894 shs	847,424 shs
SANA Sana Biotechnology	$3.67 -2.7%	$3.35	$2.61 ▼ $6.55	$1.13B	2.16	2.47 million shs	1.96 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-2.64%	-8.89%	-37.89%	-17.96%	-73.65%
AVTX Avalo Therapeutics	-0.51%	+4.01%	+5.59%	+9.64%	+114.44%
JANX Janux Therapeutics	-4.02%	-0.62%	+1.39%	+15.19%	-35.90%
SANA Sana Biotechnology	-2.65%	+7.62%	+2.80%	+19.54%	+10.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKBA Akebia Therapeutics	$0.87 -2.6%	$1.16	$0.82 ▼ $3.34	$247.51M	0.26	4.05 million shs	4.09 million shs
AVTX Avalo Therapeutics	$19.45 -0.5%	$17.69	$8.41 ▼ $24.27	$1.05B	0.8	837,998 shs	391,152 shs
JANX Janux Therapeutics	$16.00 -4.0%	$15.24	$12.12 ▼ $35.34	$1.02B	2.5	707,894 shs	847,424 shs
SANA Sana Biotechnology	$3.67 -2.7%	$3.35	$2.61 ▼ $6.55	$1.13B	2.16	2.47 million shs	1.96 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKBA Akebia Therapeutics	-2.64%	-8.89%	-37.89%	-17.96%	-73.65%
AVTX Avalo Therapeutics	-0.51%	+4.01%	+5.59%	+9.64%	+114.44%
JANX Janux Therapeutics	-4.02%	-0.62%	+1.39%	+15.19%	-35.90%
SANA Sana Biotechnology	-2.65%	+7.62%	+2.80%	+19.54%	+10.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKBA Akebia Therapeutics	2.33	Hold	$3.75	331.23% Upside
AVTX Avalo Therapeutics	2.86	Moderate Buy	$45.10	131.88% Upside
JANX Janux Therapeutics	2.50	Moderate Buy	$37.58	134.90% Upside
SANA Sana Biotechnology	2.67	Moderate Buy	$9.50	158.86% Upside

Current Analyst Ratings Breakdown

Latest AKBA, AVTX, SANA, and JANX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	AVTX Avalo Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	JANX Janux Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$35.00
8/7/2026	AVTX Avalo Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target	Buy	$50.00 ➝ $48.00
8/7/2026	JANX Janux Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$58.00 ➝ $55.00
8/7/2026	AKBA Akebia Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform	$1.00
8/7/2026	AVTX Avalo Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $30.00
8/6/2026	AKBA Akebia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/3/2026	AKBA Akebia Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/24/2026	AVTX Avalo Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
7/23/2026	SANA Sana Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/20/2026	JANX Janux Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 8/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKBA Akebia Therapeutics	$219.06M	1.10	N/A	N/A	$0.09 per share	9.66
AVTX Avalo Therapeutics	$60K	17,385.06	N/A	N/A	$8.37 per share	2.32
JANX Janux Therapeutics	$10M	97.82	N/A	N/A	$15.18 per share	1.05
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	$0.60 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKBA Akebia Therapeutics	-$5.34M	-$0.11	N/A	N/A	N/A	-13.54%	-88.88%	-7.74%	N/A
AVTX Avalo Therapeutics	-$78.26M	-$4.37	N/A	N/A	N/A	N/A	-58.03%	-48.22%	N/A
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	N/A
SANA Sana Biotechnology	-$244.17M	-$0.76	N/A	N/A	N/A	N/A	-102.39%	-39.71%	N/A

Latest AKBA, AVTX, SANA, and JANX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	SANA Sana Biotechnology	-$0.1469	-$0.13	+$0.0169	-$0.22	N/A	N/A
8/6/2026	Q2 2026	AVTX Avalo Therapeutics	-$0.5827	-$0.83	-$0.2473	-$0.83	N/A	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
8/5/2026	Q2 2026	AKBA Akebia Therapeutics	-$0.0420	-$0.02	+$0.0220	-$0.03	$48.85 million	$49.13 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
AVTX Avalo Therapeutics	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
SANA Sana Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKBA Akebia Therapeutics	0.99	1.43	1.35
AVTX Avalo Therapeutics	N/A	19.31	19.31
JANX Janux Therapeutics	N/A	16.35	16.35
SANA Sana Biotechnology	N/A	1.29	1.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKBA Akebia Therapeutics	33.92%
AVTX Avalo Therapeutics	87.06%
JANX Janux Therapeutics	75.39%
SANA Sana Biotechnology	88.23%

Insider Ownership

Company	Insider Ownership
AKBA Akebia Therapeutics	4.30%
AVTX Avalo Therapeutics	4.46%
JANX Janux Therapeutics	7.90%
SANA Sana Biotechnology	25.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKBA Akebia Therapeutics	430	277.11 million	265.19 million	Optionable
AVTX Avalo Therapeutics	40	53.63 million	51.24 million	Not Optionable
JANX Janux Therapeutics	30	61.14 million	56.31 million	Optionable
SANA Sana Biotechnology	380	299.36 million	223.32 million	Optionable

AKBA, AVTX, SANA, and JANX Headlines

Recent News About These Companies

HC Wainwright Has Pessimistic Outlook of SANA Q3 Earnings

August 13 at 7:11 AM | marketbeat.com

Analysts Are Bullish on Top Healthcare Stocks: Sana Biotechnology (SANA), Jade Biosciences (JBIO)

August 12 at 5:12 PM | theglobeandmail.com

Sana Biotechnology, Inc: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

August 11 at 10:26 AM | finanznachrichten.de

Sana Biotechnology Q2 Adjusted Loss Narrows

August 11 at 10:26 AM | finance.yahoo.com

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

August 10, 2026 | markets.businessinsider.com

Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

August 10, 2026 | marketbeat.com

Sana Biotechnology (SANA) to Release Earnings on Monday

August 9, 2026 | americanbankingnews.com

Sana Biotechnology (SANA) Projected to Release Earnings on Monday

August 3, 2026 | marketbeat.com

Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

July 29, 2026 | prnewswire.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Up 6.8% - Should You Buy?

July 27, 2026 | marketbeat.com

Sana Biotechnology, Inc. (NASDAQ:SANA) Given Consensus Rating of "Moderate Buy" by Brokerages

July 27, 2026 | marketbeat.com

Sana Biotechnology: Promising Science, But Dilution Keeps The Rating A Hold

July 25, 2026 | seekingalpha.com

Sana Biotechnology: A $1 Billion Market Cap Built On A Pre-Phase 1 Foundation

July 22, 2026 | seekingalpha.com

3 Promising Genomics Stocks to Add to Your Portfolio in 2026

July 20, 2026 | zacks.com

Sana Biotechnology (NASDAQ:SANA) Rating Lowered to "Sell" at Wall Street Zen

July 20, 2026 | marketbeat.com

Sana Biotechnology (SANA) Publishes 14 Month Diabetes Cell Therapy Results In NEJM

July 16, 2026 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 11.1% - Here's Why

July 16, 2026 | marketbeat.com

Sana (SANA) Upgraded to Buy: Here's What You Should Know

July 15, 2026 | zacks.com

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune ...

July 13, 2026 | markets.businessinsider.com

Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes

July 13, 2026 | globenewswire.com

Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026

July 1, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, AVTX, SANA, and JANX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

$0.87 -0.02 (-2.64%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$0.90 +0.03 (+2.92%)

As of 06:16 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Avalo Therapeutics NASDAQ:AVTX

$19.45 -0.10 (-0.51%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$19.50 +0.05 (+0.26%)

As of 04:41 AM Eastern

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Janux Therapeutics NASDAQ:JANX

$16.00 -0.67 (-4.02%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$16.08 +0.07 (+0.47%)

As of 04:37 AM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Sana Biotechnology NASDAQ:SANA

$3.67 -0.10 (-2.65%)

Closing price 08/13/2026 04:00 PM Eastern

Extended Trading

$3.62 -0.05 (-1.25%)

As of 05:34 AM Eastern

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, AVTX, SANA, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, AVTX, SANA, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, AVTX, SANA, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, AVTX, SANA, and JANX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Avalo Therapeutics NASDAQ:AVTX

Janux Therapeutics NASDAQ:JANX

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AKBA, AVTX, SANA, and JANX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AKBA, AVTX, SANA, and JANX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AKBA, AVTX, SANA, and JANX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, AVTX, SANA, and JANX Company Descriptions

Akebia Therapeutics NASDAQ:AKBA

Avalo Therapeutics NASDAQ:AVTX

Janux Therapeutics NASDAQ:JANX

Sana Biotechnology NASDAQ:SANA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools